NPCE

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company's Premarket Approval Panel Track Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). NeuroPace has received a communication from FD.

NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.

The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.